Participants 0 100 7
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer:
Participants 186 276 4
decreases bone loss and can increase disease-free survival in patients with breast cancer.
Participants 415 475 3
women undergoing neoadjuvant chemotherapy for breast cancer.
Participants 484 614 3
Patients were recruited for this open-label, phase 2 randomised trial between March 17, 2003, and May 19, 2006, at a single centre
Participants 616 865 10
Eligible patients had clinical stage II-III (> or = T2 and/or > or = N1) newly diagnosed breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, and normal cardiac, renal, and liver function. 120 women were randomly assigned,
Participants 1453 1584 5
Of the 120 patients initially enrolled, one withdrew after signing consent and one patient's baseline bone marrow was not available
Participants 1636 1700 3
At 3 months, 109 bone-marrow samples were available for analysis
